8-K: Pennant Group Reports Record Q3 Growth, Boosts 2025 Outlook

The Pennant Group, Inc. announced strong third-quarter 2025 results with record operational metrics and an updated positive full-year guidance, following a major acquisition.

Summary

• GAAP diluted earnings per share for Q3 2025 was $0.17, while adjusted diluted earnings per share reached $0.30.
• Total revenue for the third quarter increased by 26.8% to $229.0 million compared to the prior year quarter.
• Net income for the third quarter was $6.1 million, a 2.0% decrease from the prior year, but adjusted net income grew 27.6% to $10.4 million.
• Consolidated Adjusted EBITDAR for Q3 2025 was $29.3 million, a 12.8% increase, and Consolidated Adjusted EBITDA was $17.3 million, up 14.5%.
• The Home Health and Hospice Services segment saw revenue increase by 27.9% to $173.6 million, with total home health admissions up 36.2% to 20,426 and hospice average daily census up 17.4% to 4,044.
• The Senior Living Services segment reported a 23.2% revenue increase to $55.5 million, with average occupancy rising 180 basis points to 80.9% and average monthly revenue per occupied room increasing 7.4% to $5,195.
• On October 1, 2025, the company completed its largest-ever acquisition of 54 home health, hospice, and home care operations from UnitedHealth Group and Amedisys, expanding into the Southeast.
• Updated 2025 annual guidance anticipates total revenue between $911.4 million and $948.6 million, adjusted earnings per diluted share between $1.14 and $1.18 (midpoint $1.16, representing 23.4% growth over 2024), and adjusted EBITDA between $70.9 million and $73.8 million.

Sentiment

Score: 8

Explanation: The filing indicates strong operational performance with record metrics across segments, significant revenue and adjusted earnings growth, and a major strategic acquisition. While GAAP net income saw a minor decrease, adjusted metrics and forward guidance are very positive, suggesting robust underlying business health and growth trajectory.

Positives

• Total revenue for Q3 2025 increased by $48.4 million or 26.8% over the prior year quarter to $229.0 million.
• Adjusted net income for Q3 2025 increased by $2.3 million or 27.6% over the prior year quarter to $10.4 million.
• Consolidated Adjusted EBITDAR for Q3 2025 increased by $3.3 million or 12.8% over the prior year quarter to $29.3 million.
• Consolidated Adjusted EBITDA for Q3 2025 increased by $2.2 million or 14.5% over the prior year quarter to $17.3 million.
• Home Health and Hospice Services segment revenue increased by $37.9 million or 27.9% over the prior year quarter to $173.6 million.
• Home Health and Hospice Services segment adjusted EBITDAR from operations increased by $5.3 million or 22.5% over the prior year quarter to $29.1 million.
• Home Health and Hospice Services segment adjusted EBITDA from operations increased by $5.0 million or 22.7% over the prior year quarter to $26.8 million.
• Total home health admissions for Q3 2025 increased by 5,433 or 36.2% over the prior year quarter to 20,426.
• Total Medicare home health admissions for Q3 2025 increased by 2,150 or 35.4% over the prior year quarter to 8,221.
• Hospice average daily census for Q3 2025 increased by 600 or 17.4% compared to the prior year quarter to 4,044.
• Senior Living Services segment revenue increased by $10.5 million or 23.2% over the prior year quarter to $55.5 million.
• Senior Living average occupancy for Q3 2025 increased by 180 basis points over the prior year quarter to 80.9%.
• Senior Living average monthly revenue per occupied room for Q3 2025 increased by $359 or 7.4% over the prior year quarter to $5,195.
• Senior Living segment adjusted EBITDAR from operations increased by $1.9 million or 14.1% over the prior year quarter to $15.3 million.
• Senior Living segment adjusted EBITDA from operations increased by $1.2 million or 26.2% over the prior year quarter to $5.6 million.
• Completed the largest transaction in company history with the acquisition of 54 home health, hospice, and home care operations from UnitedHealth Group and Amedisys on October 1, 2025.
• Updated 2025 earnings guidance midpoint of $1.16 represents 23.4% growth on 2024 adjusted earnings per share.

Negatives

• GAAP diluted earnings per share for Q3 2025 decreased to $0.17 from $0.20 in the prior year quarter.
• Net income for Q3 2025 decreased by $0.1 million or 2.0% over the prior year quarter to $6.1 million.

Risks

• Reduced prices and reimbursement rates for services.
• Ability to acquire, develop, manage, or improve operations.
• Ability to manage increasing borrowing costs as additional indebtedness is incurred to fund the acquisition and development of operations.
• Ability to access capital on a cost-effective basis to continue to successfully implement the growth strategy.
• Operating margins and profitability could suffer if unable to grow and manage effectively the increasing number of operations.
• Competition from other companies in the acquisition, development, and operation of facilities.
• Ability to defend claims and lawsuits, including professional liability claims alleging services resulted in personal injury, and other regulatory-related claims.
• Application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit business operations, require significant expenditures, or limit the ability to relocate operations if necessary.

Future Outlook

Management has provided updated 2025 annual guidance, anticipating total revenue between $911.4 million and $948.6 million, adjusted earnings per diluted share between $1.14 and $1.18, and adjusted EBITDA between $70.9 million and $73.8 million. The guidance reflects continued strong operational performance across segments and the integration of the recently acquired UnitedHealth and Amedisys assets, which are expected to be in a transitional phase during the fourth quarter of 2025. The updated earnings guidance midpoint of $1.16 represents 23.4% growth over 2024 adjusted earnings per share.

Management Comments

• Brent Guerisoli, CEO: "In the third quarter we achieved record breaking performance in each of our segments, including all-time highs in senior living occupancy, hospice average daily census, and home health admissions."
• Brent Guerisoli, CEO: "These results demonstrate the power of our model to drive strong same-store improvement through periods of dynamic growth."
• Brent Guerisoli, CEO: "Our updated earnings guidance midpoint of $1.16 represents 23.4% growth on our 2024 adjusted earnings per share. Our guidance update is based on continued strong operational performance across our segments and the addition of the UnitedHealth and Amedisys assets, which will be in a transitional phase during the fourth quarter of 2025."
• John Gochnour, COO: "On October 1, we completed the acquisition of 54 home health, hospice and home care operations from UnitedHealth Group and Amedisys. We are thrilled to welcome a new group of talented leaders and clinicians to the Pennant family."
• John Gochnour, COO: "This is the largest transaction we’ve completed in our history, but it fits squarely within our disciplined acquisition strategy. We are well-positioned to effectively transition and unlock additional potential in these assets and further expansion in the region."
• Lynette Walbom, CFO: "We believe providing updated annual adjusted consolidated EBITDA guidance in addition to updated annual revenue and adjusted earnings per share guidance is helpful to understanding our expectations for our business and operational cash flow."

Industry Context

The Pennant Group's strong performance and strategic acquisition align with broader trends in the healthcare services industry, particularly the growing demand for home health, hospice, and senior living services driven by an aging population and a preference for care in less institutional settings. The expansion into the Southeast through a significant acquisition indicates a consolidation trend and a focus on geographic market penetration to capture a larger share of these growing segments. The company's ability to achieve 'record breaking performance' and 'strong same-store improvement' suggests effective operational models in a competitive and evolving regulatory environment.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong financial performance, strategic growth through acquisition, and positive future guidance. The slight dip in GAAP EPS might be a minor concern but is offset by adjusted EPS growth.
• Employees: The acquisition of 54 operations from UnitedHealth Group and Amedisys means welcoming a new group of talented leaders and clinicians, potentially expanding career opportunities and the company's talent pool.
• Customers/Patients: Expansion into new communities in the Southeast allows more individuals to experience the Pennant model and its services, potentially increasing access to home health, hospice, and senior living care.
• Creditors: The mention of increasing borrowing costs to fund acquisitions suggests potential for higher debt levels, which could impact credit risk, though the strong operational cash flow might mitigate this.

Next Steps

• A live webcast and conference call will be held on November 6, 2025, at 10:00 a.m. Mountain time (12:00 p.m. Eastern time) to discuss the third quarter 2025 financial results.
• The company will post an updated investor presentation on its website (investor.pennantgroup.com) for use at upcoming investor meetings.
• The acquired UnitedHealth and Amedisys assets will be in a transitional phase during the fourth quarter of 2025.

Key Dates

Recommendation

The Pennant Group's Q3 2025 results demonstrate exceptional operational strength, marked by record-breaking performance across all segments, significant revenue growth (26.8%), and robust adjusted earnings growth (27.6%). The strategic acquisition of 54 operations from UnitedHealth Group and Amedisys is a transformative move, expanding the company's footprint and future growth potential. Despite a minor dip in GAAP net income, the overall trajectory, coupled with an upward revised 2025 guidance (23.4% adjusted EPS growth), signals strong momentum and effective management. The company is well-positioned to capitalize on the growing demand for healthcare services, making it an attractive investment for long-term growth.

Keywords

Home Health, Hospice, Senior Living, Healthcare Services, Acquisition, Earnings, Revenue Growth, Occupancy, Admissions, EBITDA, EBITDAR, Guidance, NASDAQ: PNTG